Aberrant progenitors common to megakaryocytic and myeloid cells in a Down's infant with transient abnormal myelopoiesis

Satō, Atsushi; Imaizumi, Masue; Noro, Takeshi; Ichinohasama, Ryo; Saito, Toshiaki; Yoshinari, Miyako; Suwabe, Naruyoshi; Suzuki, Hoshiro; Koizumi, Yoshitsugu; Cui, Yan; Yamamoto, Masayuki; Iinuma, Kazuie

doi:10.1016/0145-2126(95)00065-8

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transduction of stem cells can introduce genes into multiple cell lineages and lead to stable expression of the transgene for long periods of time. The discovery of stem cell plasticity revealed significant opportunities for all types of cell-based therapy [34][35][36][37][38][39][40][41][42][43][44][45][46] and provided insight into the molecular and functional heterogeneity of stem cell populations and understanding of their transdifferentiation potential. 47,48 Hematopoietic stem cell vehicles.…”

Section: Differentiated Immune Cell Vehiclesmentioning

confidence: 99%

Gene-modified bone marrow cell therapy for prostate cancer

Wang

Thompson

2008

Gene Ther

View full text Add to dashboard Cite

There is a critical need to develop new and effective cancer therapies that target bone, the primary metastatic site for prostate cancer and other malignancies. Among the various therapeutic approaches being considered for this application, gene-modified cell-based therapies may have specific advantages. Gene-modified cell therapy uses gene transfer and cell-based technologies in a complementary fashion to chaperone appropriate gene expression cassettes to active sites of tumor growth. In this paper, we briefly review potential cell vehicles for this approach and discuss relevant gene therapy strategies for prostate cancer. We further discuss selected studies that led to the conceptual development and preclinical testing of IL-12 gene-modified bone marrow cell therapy for prostate cancer. Finally, we discuss future directions in the development of gene-modified cell therapy for metastatic prostate cancer, including the need to identify and test novel therapeutic genes such as GLIPR1.

show abstract